1. Alnylam Elects Amy Schulman to its Board of Directors

    Alnylam Elects Amy Schulman to its Board of Directors

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer’s Consumer Healthcare business. She currently serves on the faculty ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board.
    2. I am excited to join the Board of Alnylam, a first-in-class innovation-based biotechnology company, and a pioneer in advancing an entirely new class of high impact medicines with RNAi therapeutics.
  3. Topics Mentioned